年轻成人降脂治疗的成本效益分析
本研究基于美国NHANES调查和CVD政策模型,评估无ASCVD年轻成人(18-39岁)LDL-C升高患病率及降脂策略的成本效益。约27%的年轻成人LDL-C≥130 mg/dL,9%≥160 mg/dL。与标准治疗相比,他汀或强化生活方式干预可预防终身ASCVD事件并增加QALYs;男性LDL-C≥130 mg/dL时他汀的ICER为31,000美元/QALY,女性为106,000美元/QALY,强化生活方式干预成本更高且效果更差。
要点
- 约27%无ASCVD年轻成人LDL-C≥130 mg/dL,9%≥160 mg/dL。
- 年轻成人他汀降脂可预防终身ASCVD事件并增加QALYs。
- 男性LDL-C≥130 mg/dL他汀极具成本效益,女性为中等成本效益。
核心结论
- 对LDL-C≥130 mg/dL的年轻男性他汀治疗极具成本效益,对年轻女性为中等成本效益。
研究设计与样本
- 基于美国NHANES调查估计LDL-C升高患病率,并利用CVD政策模型预测终身QALYs、医疗费用和ICERs。
- 标准治疗定义为≥40岁成人根据LDL-C、ASCVD风险或糖尿病接受他汀,加上年轻成人LDL-C≥190 mg/dL者。
- 模拟在年轻成人LDL-C≥160 mg/dL或≥130 mg/dL时,在标准治疗基础上加用中等强度他汀或强化生活方式干预。
主要发现
- 约27%无ASCVD年轻成人LDL-C≥130 mg/dL,9%≥160 mg/dL。
- 与标准治疗相比,年轻成人他汀或生活方式干预可预防终身ASCVD事件并增加QALYs。
- 年轻男性LDL-C≥130 mg/dL他汀的ICER为31,000美元/QALY,年轻女性为106,000美元/QALY。
- 强化生活方式干预比他汀治疗成本更高且效果更差。
临床怎么用
- 对LDL-C≥130 mg/dL的年轻男性可考虑他汀治疗以改善长期成本效益。
- 对LDL-C≥130 mg/dL的年轻女性他汀治疗具中等成本效益,决策需个体化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Raised low-density lipoprotein cholesterol (LDL-C) in young adulthood (aged 18-39 years) is associated with atherosclerotic cardiovascular disease (ASCVD) later in life. Most young adults with elevated LDL-C do not currently receive lipid-lowering treatment. OBJECTIVES: This study aimed to estimate the prevalence of elevated LDL-C in ASCVD-free U.S. young adults and the cost-effectiveness of lipid-lowering strategies for raised LDL-C in young adulthood compared with standard care. METHODS: The prevalence of raised LDL-C was examined in the U.S. National Health and Nutrition Examination Survey. The CVD Policy Model projected lifetime quality-adjusted life years (QALYs), health care costs, and incremental cost-effectiveness ratios (ICERs) for lipid-lowering strategies. Standard care was statin treatment for adults aged ≥40 years based on LDL-C, ASCVD risk, or diabetes plus young adults with LDL-C ≥190 mg/dL. Lipid lowering incremental to standard care with moderate-intensity statins or intensive lifestyle interventions was simulated starting when young adult LDL-C was either ≥160 mg/dL or ≥130 mg/dL. RESULTS: Approximately 27% of ASCVD-free young adults have LDL-C of ≥130 mg/dL, and 9% have LDL-C of ≥160 mg/dL. The model projected that young adult lipid lowering with statins or lifestyle interventions would prevent lifetime ASCVD events and increase QALYs compared with standard care. ICERs were US$31,000/QALY for statins in young adult men with LDL-C of ≥130 mg/dL and US$106,000/QALY for statins in young adult women with LDL-C of ≥130 mg/dL. Intensive lifestyle intervention was more costly and less effective than statin therapy. CONCLUSIONS: Statin treatment for LDL-C of ≥130 mg/dL is highly cost-effective in young adult men and intermediately cost-effective in young adult women.
引用
- Kohli-Lynch CN, Bellows BK, Zhang Y, et al. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. J Am Coll Cardiol. 2021. PMID: 34763772. doi:10.1016/j.jacc.2021.08.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。